Floatz logo

(3RS)-1-(6-(.ALPHA.-METHYLPOLY(OXYETHYLENE)AMINO)-6-OXOHEXYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINAMIDE, (20000 MW)

Peritoneal Metastases

Lumicell, Inc.OtherPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Peritoneal Metastases cohort.

Asset / SponsorPhaseRating
Irinotecan
Catharina Ziekenhuis Eindhoven
Phase 3BB
(+)-VINCRISTINE
Catharina Ziekenhuis Eindhoven
Phase 2CCC
Recombinant Mutant Human Tumor Necrosis Factor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2CCC
rc48-adc
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 1/2CCC
Tislelizumab
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 1/2CCC

View all 12 →

Same molecule, other indications

(3RS)-1-(6-(.ALPHA.-METHYLPOLY(OXYETHYLENE)AMINO)-6-OXOHEXYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINAMIDE, (20000 MW) is also rated in:

breast cancerDormant
CCC
Indicative ·
50 / 100
View asset →
Neoadjuvant TherapyDormant
CC
Indicative ·
46 / 100
View asset →
Neoplasm, ResidualDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →